SLCO1B3 T334G polymorphisms and mycophenolate mofetil-related adverse reactions in kidney transplant recipients

Area of Science:

• Pharmacogenomics
• Transplantation Medicine
• Clinical Pharmacology

Background:

• Mycophenolate mofetil (MMF) is a key immunosuppressant post-kidney transplantation.
• Adverse reactions to MMF can impact patient outcomes.
• The role of SLCO1B3 T334G genetic variations in MMF adverse events remains unclear.

Purpose of the Study:

• To investigate the association between SLCO1B3 T334G polymorphisms and MMF-related adverse reactions in kidney transplant recipients.
• To identify potential genetic predictors of MMF intolerance.

Main Methods:

• A retrospective study involving 111 kidney transplant recipients.
• Patients were categorized based on experienced adverse effects.
• Clinical data and MMF concentrations were analyzed, focusing on SLCO1B3 T334G genotype.

Main Results:

• The frequency of the G allele in the SLCO1B3 T334G polymorphism was significantly higher in patients experiencing gastrointestinal reactions compared to those without adverse effects (p < 0.05).
• Logistic regression analysis identified the SLCO1B3 T334G genotype as an independent risk factor for MMF-induced gastrointestinal reactions.

Conclusions:

• The SLCO1B3 T334G GG genotype is associated with an increased likelihood of gastrointestinal adverse reactions to mycophenolate mofetil.
• This genetic polymorphism may serve as a predictive marker for MMF-related gastrointestinal toxicity in kidney transplant recipients.